Diagnostics company BG Medicine went public last week. It closed at $8.39 - an increase of 5 percent. The money raised through this public offering will be used to launch its launch of its BGM galectin-3 biomarker test.
BG Medicine, which has created a biomarker test to determine heart-attack risk, saw its stock jump more than 10 percent on Friday. The company won FDA approval for its test by the end of last year and went public to fund the rollout.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.